Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors

Introduction: The clinical successes seen with anti–programmed cell death protein 1/programmed death-ligand 1 (anti–PD-[L]1) agents have galvanized the field of immuno-oncology. We evaluated the landscape and trends in immunotherapy trials involving the PD-(L)1 axis in intrathoracic tumors. Methods:...

Full description

Bibliographic Details
Main Authors: Samuel A. Kareff, MD, MPH, Suraj Samtani, MD, Mauricio Burotto, MD, MSc, Vinay Prasad, MD, MPH, Chul Kim, MD, MPH
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:JTO Clinical and Research Reports
Subjects:
PD-(L)1 axis
NSCLC
SCLC
Mesothelioma
TET
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000084

Similar Items

Similar Items